LLY

1,113.43

-0.94%↓

JNJ

231.6

-0.55%↓

ABBV

220.11

-0.18%↓

UNH

407.02

-0.34%↓

NVS

151.67

+1.28%↑

LLY

1,113.43

-0.94%↓

JNJ

231.6

-0.55%↓

ABBV

220.11

-0.18%↓

UNH

407.02

-0.34%↓

NVS

151.67

+1.28%↑

LLY

1,113.43

-0.94%↓

JNJ

231.6

-0.55%↓

ABBV

220.11

-0.18%↓

UNH

407.02

-0.34%↓

NVS

151.67

+1.28%↑

LLY

1,113.43

-0.94%↓

JNJ

231.6

-0.55%↓

ABBV

220.11

-0.18%↓

UNH

407.02

-0.34%↓

NVS

151.67

+1.28%↑

LLY

1,113.43

-0.94%↓

JNJ

231.6

-0.55%↓

ABBV

220.11

-0.18%↓

UNH

407.02

-0.34%↓

NVS

151.67

+1.28%↑

Search

PerkinElmer Inc

Open

SectorHealthcare

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

-58M

41M

Sales

-61M

711M

P/E

Sector Avg

48.341

49.712

EPS

1.06

Dividend yield

0.28

Profit margin

5.726

Employees

11,000

EBITDA

-38M

180M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+3.18% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.28%

2.36%

Next Earnings

27 lip 2026

Next Dividend date

7 sie 2026

Next Ex Dividend date

17 lip 2026

Market Stats

By TradingEconomics

Market Cap

1.5B

11B

Previous open

0

Previous close

0

News Sentiment

By Acuity

36%

64%

114 / 342 Ranking in Healthcare

PerkinElmer Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

About PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat